Medytox dismissed rumors that the Chinese authority would suspend the screening of the botulinum toxin "Meditoxin" that was expected to be licensed in China in the first half of the year.
Medytox said on its website on June 5 that it has not received any notification from China Food and Drug Administration (CFDA) that it will suspend the screening process of Meditoxin's license, and that those who will spread false information will be held fully responsible.
The rumor that Meditoxin was suspended from screening for Chinese license was raised by a news outlet. According to the report, the CFDA decided to suspend the license screening process after local science and technology media outlets dealt with negative suspicions regarding the manufacturing process of Medytox, which was recently raised in Korea.
Medytox, however, explained that the screening process for approval of Meditoxin, which is being carried out at CFDA, is in the process of reviewing final documents.
A Medytox official said, "The kind of noises that have been happening recently with the company are being caused by malicious tip-offs from former Medytox employees who have colluded with Daewoong Pharmaceutical, and will be over when Daewoong is found guilty of stealing strains and manufacturing process materials."